Matal
02 Mar 2018
Re: Interesting to see... Could be, although there are plenty of similar tiny Pharma companies who come and go, promising much but end up disappearing... VEC might as well do something with the cash pile. Come results time maybe they'll want to do another share buy back! Wouldn't THAT be exciting! I didn't understand the rational for maximising only a £15 million spend. IMO that minuscule amount was never going to make any beneficial difference whatsoever on the sp level whilst the buying was going on and it looks to be now proving that the sp level won't change now it's finished. To me it was just a throw away of 15 million quid and a PR exercise of all show and no trousers! I believe the level we are at with the sp is purely down to shorts making the most of market sentiment that has a general expectation that another refusal is on its way for the Advair generic, together with low expectations of getting any joy out of the GSK litigation issue in December.
raptor66
02 Mar 2018
Re: Interesting to see... Verona Pharma might be a good add-on for VEC??[link]
Matal
01 Mar 2018
Re: Interesting to see... raptor66' yep, agreed. The £15 million quids worth of buy back was a relative drop in the ocean, which is why there shouldn't be much change in th sp level now it's ended. Shorts are making hay whilst the sun shines on the uncertainty surrounding the generic. When that is resolved and the knee jerk action we can expect in the event of another refusal is taken care of... hopefully it will recover to a more realistic book value. If the shorts have to run to cover and buy the 25-30 million shares that are now shorted if the decision goes VEC's way... the sp should sky rocket!
raptor66
01 Mar 2018
Re: Interesting to see... I do not think the relative number of shares bought every day by the Company made much difference to the sp in usual day trading. It does bewilder me what was the point, it did not stop the sp avalanche. I would have welcomed a one-off special dividend instead.On Advair front, after Vectura and Mylan, the third contender for Advair generic is in fact 'Norvatis', equally rejected by the FDA.
Matal
01 Mar 2018
Interesting to see... what happens to the sp now the buy back has been completed.
d gaser
22 Feb 2018
MHRA recall serratide Accuhaler inhalers It appears that the The Medicines and Healthcare products Regulatory Agency (MHRA) has urged asthma patients to replace specific batches of their Ventolin Accuhaler inhalers, that are used for the emergency relief of asthmatic symptoms, after it was discovered that a manufacturing issue resulted in some devices not delivering the full dose required.In addition, one lot of Seretide Accuhaler, used for the maintenance of preventative treatment of asthma, is also being recalled from hospitals, pharmacies, dispensing practices, retailers and wholesalers in the UK. The MHRA said that other asthma inhalers, including the more commonly used Ventolin Evohaler are not affected.Bernadette Sinclair Jenkins, the regulatory assessment unit manager of the MHRA’s Inspections, Enforcement and Standards unit, said: “It is important people check whether they have an affected inhaler. We want patients and their families to be confident treatment will be safe and effective when required.”www.msn.com/en-gb/news/uknews/thousands-of-inhalers-recalled-after-manufacturing-issue/ar-BBJqdFV
Matal
22 Feb 2018
Good news for UltibroBreezhaler Data published in the Lancet Respiratory Medicine Basel, February 22, 2018 - Novartis today announced the publication of the CLAIM* study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium 110/50 mcg) significantly improved lung and cardiac function, when compared to placebo, in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation[1].Many people living with COPD are at increased risk of death and disability due to comorbid cardiovascular disease[2]. Lung hyperinflation is common in people with COPD[3], and has been linked to impaired cardiac function and a worsening of COPD symptoms, especially breathlessness[4]-[6]. CLAIM is the first study to investigate the effects of dual bronchodilation on cardiac function and lung hyperinflation[1].The CLAIM study met its primary endpoint demonstrating that treatment with Ultibro Breezhaler led to decreased lung hyperinflation and improvements in cardiac function** after 14 days of treatment[1]. This translated into clinically relevant patient benefits of improved health status and breathlessness (dyspnea), studied as exploratory endpoints[1]."Lung hyperinflation is often associated with impaired cardiac function in patients with COPD," said Shreeram Aradhye, Chief Medical Officer and Global Head of Medical Affairs for Novartis Pharmaceuticals. "The publication of the CLAIM study is important for any COPD patient with signs of lung hyperinflation. For the first time, we demonstrated that treatment with Ultibro Breezhaler can reduce lung hyperinflation and improve cardiac function, breathlessness and health status."In the CLAIM study Ultibro Breezhaler was well tolerated and its safety profile was comparable with placebo[1].About the CLAIM studyThe CLAIM study was a randomized, double-blinded, placebo-controlled, single-center, two period cross-over study comparing the effects of 14-day Ultibro® Breezhaler® therapy with placebo on cardiac and lung function in hyperinflated COPD patients[1]. It involved a total of 62 patients, of whom 57 completed both treatment periods[1]. All patients had moderate-to-very severe COPD and confirmed lung hyperinflation (residual volume >135% predicted).[1]The primary endpoint of the study was to demonstrate the effect of 14-day once-daily Ultibro Breezhaler treatment on left ventricular end-diastolic volume (LV-EDV) as measured by MRI[1]. Secondary endpoints included effects on lung function parameters as measured by residual volume (RVol), forced expiratory volume in one second (FEV1) and forced vital capacity (FVC)[1].Cardiac assessments included right ventricular end-diastolic volume (RV-EDV), left and right ventricular stroke volume (LV-SV and RV-SV), left and right ventricular end-systolic volumes (LV-ESV and RV-ESV) and cardiac index (CI)[1].
d gaser
21 Feb 2018
shorting has been increased I have Just taken another look at short tracker to see who is still shorting VEC ,and it appears that another company has joined the 4 previous , and the quantity now stands at 3.50% of VEC stock (see the link below) How ever if they all closed their shorts at the same time ,and that will probably be the second week of March ,as that's when VEC release the full years accounts, this should fly .The accounts are being published on Wednesday 21 March, hopefully that will be the catalyst for good news as well . As for any take over, if any body is going to do it ,then it would proberly be the Chinnese as they all ready have an interrest . BE HAPPYDAVE [link]
Matal
20 Feb 2018
Re: Teva Hikma have appointed a new CEO, formally CEO of Teva's Global Generic Medicines Group, effective immediately. Being seen by the market as positive news for Hikma.
Matal
18 Feb 2018
Teva A more 'real' slice of the 'speculation pie' to make of it what you will: Anyone notice that Buffort has just bought into Teva via his Berkshire Hathaway vehicle! Make that HIKMA! I wonder why!
Matal
18 Feb 2018
Re: Multiple bid rumours/200p Yep, I'm certainly suspicious at whats been happening! Even with a new FDA resolution possibly not happening till the end of March... It looks to me like things are now converging and some change in the prevailing abysmal circumstances could happen well before anymore new news from the FDA is heard. Have to see if they get better or worse! I think it's going to be rather interesting to see if whoever it is thats been dumping large portions on the market, (no RNS seems to point to the seller being outside our disclosure rules!) suddenly stops doing that at the same time as the buy back scheme gets completed! That scheme is all but finished now and I'm hoping that the removal of a guaranteed buyer from the market should at least have SOME effect on market sentiment... we should/could have a chance of then getting a more realistic idea of what a 'none rigged' sp actually looks like! The other side of the coin is IF the dumper keeps dumping without VEC around to do some hoovering up... then further lows could be in prospect... likewise, and despite how low its already fallen... if the FDA issues another refusal then market sentiment and despondency will almost certainly see even further lows for a while!
raptor66
18 Feb 2018
Re: Multiple bid rumours/200p Matal, your post does make sense. Markets are rigged and it could have been anyone of those I call 'market molesters' kicked off the take over rumour late December last year, got punters to pile in and then pulled the rug.
Matal
18 Feb 2018
Re: Multiple bid rumours/200p The Telegraph reported that 'sources' said GSK/VEC take over rumours were swirling around. It offered no indication who it's 'sources' are attached to and not a single shred of evidence (either back then OR since) as to the truth of those supposed 'rumours'. IMO there is no way GSK would want to pay £1 BILLION just to stop the advent of an Advair generic from HIKMA/VEC getting to market... OR to get their hands on a £100 million cash pile (now depleted by £15 due to buy out costs!) Are GSK also going to also buy out other potential solutions in order make out like King Canute! I think the 'rumour' was a plant by vested interests, there is not a grain of truth in it. In the new GSK CEO's recent narrative, she indicated she has no interest any M & A activity and there is none planned for the near future. In anycase no sensible offer could possibly made with the FDA on the brink of issuing a new adjudication which will have such obvious and far reaching implications for VEC. The IP patents for the Eliptica products which VEC claim royalties should continue to be payable by GSK till 2021... are capped at around £13.5 million per annum. For the period in question, 2015-2021 when the patents are supposed to expire anyway... the payments would not exceed £100 million. GSK have the option of withdrawing and agreeing to backdate payments and continue paying the royalties or possibly making a suitable 'out of court' offer. Either way they are not going to pay £1 BILLION to stop the court case! VEC's ongoing royalty payments from the likes of Pacira are hardly likely to persuade GSK to buy out VEC for a £billion either!
raptor66
18 Feb 2018
Re: Multiple bid rumours/200p This dog is not alone in its recent sp collapse, the drop is not all due to the company fundamentals but the market molesters possibly shifting funds to bonds from equities in anticipation of interest rate rises. I do hope the results next month settles some nerves?? As for takeover speculations, GSK would be more likely contender imo, because it has been specifically mentioned that the generic Advair may become available this year by their CEO and in their recent results. If it is Vec's Advair (I hope it is) than just buying out Vec would mean GSK can keep their Advair price high. Plus £100m Vecs cash, and buy out of their litigators.
dave297
17 Feb 2018
Re: Multiple bid rumours/200p After much deliberation,consideration & analysis I have concluded that I would reluctantly scratch the limbs off any fool prepared to offer me 200p for each & every share I hold in this dog 😂
